{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:50:31Z","timestamp":1778086231255,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>P\u2010Loop mutations in CML patients prevent the conformational change in BCR\u2010ABL1 necessary for drug binding. The present study aimed to evaluate the impact of mutations in this domain on the prognosis of the disease and also to associate the baseline Sokal relative risk score with the overall survival in non\u2010responding CML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Blood samples were analyzed using ARMS\u2010PCR and then an association was assessed between presence\/absence of mutations, hematological and molecular response, disease progression, overall survival, and Sokal score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the total 250 CML patients, 102 were found to be treatment\u2010resistant. Fifty\u2010three patients harbored P\u2010Loop mutations with G250E (12.7%) being most frequent. Complete hematological response and major molecular response were achieved by only 27.7% and 5.7 patients, respectively. Worst survival (57.1%) was observed in Y253H positive patients while according to Sokal score in high\u2010risk patients harboring Y253F (50%) and E255V (50%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The presence of P\u2010Loop domain mutations negatively impacted the prognosis of the disease in terms of disease advancement and overall survival. So, the timely performance of the BCR\u2010ABL1\u00a0mutational analysis and the modifications in the treatment plan based on the mutation identified would help in a better outcome of the disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.13798","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T04:08:15Z","timestamp":1642738095000},"page":"538-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["P\u2010Loop mutations\u2014Negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients"],"prefix":"10.1111","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-0672","authenticated-orcid":false,"given":"Bushra","family":"Kaleem","sequence":"first","affiliation":[{"name":"Department of Clinical Research National Institute of Blood Disease and Bone Marrow Transplantation Karachi Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Shahab","sequence":"additional","affiliation":[{"name":"Department of Clinical Research National Institute of Blood Disease and Bone Marrow Transplantation Karachi Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzma","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology National Institute of Blood Disease and Bone Marrow Transplantation Karachi Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahir Sultan","family":"Shamsi","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology National Institute of Blood Disease and Bone Marrow Transplantation Karachi Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90124-3"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2408149"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.007"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.004"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-009-0046-y"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2322-2"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"issue":"5","key":"e_1_2_11_16_1","first-page":"659","article-title":"Comparison of allele specific oligonucleotide\u2010polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"91","author":"Kang HY","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07679-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162140299"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3472"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903332486"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.894"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.2122.2122"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.004023"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/312071a0"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.10.6868-6878.1994"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.32.19585"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802714032"},{"key":"e_1_2_11_29_1","first-page":"337","article-title":"The P\u2010Loop mutations Y253H and E255K\/V may develop more frequently than T315I during nilotinib therapy after imatinib failure and are associated with progression in patients with Ph\u2010positive leukemia","volume":"92","author":"Branford S","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.320.320"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1940.1940"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.13798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.13798","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.13798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:33:24Z","timestamp":1692819204000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.13798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/ijlh.13798"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.13798","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"2021-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}